Developer · United States
Emalex Biosciences Inc.
Emalex Biosciences was a Chicago-based clinical-stage biopharmaceutical company (a Paragon Biosciences portfolio company) developing ecopipam, a first-in-class selective dopamine D1 receptor antagonist, for pediatric Tourette syndrome and other CNS disorders. The company was acquired by Teva Pharmaceutical Industries in June 2026.
Pipeline (1)
- Tourette syndromeFiled (NDA)Active
Deals & partnerships
- EcopipamLed by Teva Pharmaceutical Industries Ltd.Licensor Psyadon Pharmaceuticals, Inc.
- Jun 10, 2026AcquisitionTeva closes acquisition of Emalex BiosciencesTeva closed its acquisition of Emalex Biosciences ($700 million upfront at closing; up to $200 million in commercial milestones plus net sales-based royalties, subject to approval). Ecopipam is now a Teva asset; U.S. NDA submission reiterated for H2 2026. This explains emalexbiosciences.com redirecting to tevapharm.com.
- Apr 29, 2026AcquisitionTeva to acquire Emalex Biosciences for $700M upfront, adding NDA-ready ecopipamTeva agreed to acquire Emalex Biosciences for $700 million in cash upfront plus up to $200 million in commercial milestones and net sales-based royalties, adding ecopipam (first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome, FDA Orphan Drug + Fast Track). Close expected Q3 2026; NDA submission guided for H2 2026.
- Aug 14, 2018AcquisitionEmalex Biosciences acquires Psyadon Pharmaceuticals, gaining ecopipam rightsEmalex Biosciences acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation, for the treatment of pediatric Tourette syndrome in patients under 16 years of age. Psyadon had advanced ecopipam through Phase 2b prior to the acquisition.
Catalysts · 1 upcoming · 3 reported
- Late Q1 2027Anticipated
EcopipamforTourette syndromeRegulatory
FDA PDUFA action on ecopipam NDA targeted late Q1 2027 (Priority Review)
Recently reported
- 2026-06-18
EcopipamforTourette syndromeRegulatory
Teva submitted the U.S. NDA for ecopipam in pediatric Tourette syndrome (guided for 2H 2026; submitted 2026-06-18).
- 2026-05-26met
EcopipamforTourette syndromeTopline data
D1AMOND Phase 3 met primary and secondary endpoints: ecopipam delayed time to relapse vs placebo in pediatric (HR=0.5, p=0.0084) and combined (HR=0.5, p=0.0050) Tourette populations; published in JAMA Neurology.
- 2026-05-26met
EcopipamforTourette syndromeFull results
Phase 3 randomized-withdrawal full results published in JAMA Neurology: ecopipam halved relapse risk (pediatric HR 0.47, p=.008)
Recent activity
- Jun 18, 2026ReadoutEcopipam·Tourette syndromeTeva submitted the U.S. NDA for ecopipam in pediatric Tourette syndrome (guided for 2H 2026; submitted 2026-06-18).source ↗
- May 26, 2026ReadoutEcopipam·Tourette syndromemetD1AMOND Phase 3 met primary and secondary endpoints: ecopipam delayed time to relapse vs placebo in pediatric (HR=0.5, p=0.0084) and combined (HR=0.5, p=0.0050) Tourette populations; published in JAMA Neurology.source ↗
- May 26, 2026ReadoutEcopipam·Tourette syndromemetPhase 3 randomized-withdrawal full results published in JAMA Neurology: ecopipam halved relapse risk (pediatric HR 0.47, p=.008)source ↗
- Feb 4, 2025Phase changeEcopipam·Tourette syndromePhase 3D1AMOND Phase 3 completed (primary completion 2025-01-13; study completion 2025-02-04); met primary and secondary endpoints.source ↗
- Jan 31, 2023Phase changeEcopipam·Tourette syndromePhase 3Pivotal Phase 3 randomized-withdrawal study D1AMOND (NCT05615220) started (first patient dosed).source ↗
- Sep 23, 2021Phase changeEcopipam·Tourette syndromePhase 2Phase 2b in children/adolescents with Tourette syndrome (NCT04007991, n=153) completed (primary completion 2021-09-23).source ↗
Competitive landscape
Other companies developing against Emalex Biosciences Inc.'s targets or indications.
